Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Maternal-Fetal Medicine · Glucokinase maturity-onset diabetes of the young (GCK-MODY)

How Is Fetal Growth Monitored in GCK-MODY Pregnancy?

At a Glance

In a GCK-MODY pregnancy, serial ultrasound measurements of the baby's abdominal circumference can suggest whether the baby inherited the GCK variant and help guide insulin decisions, but only genetic testing can confirm inheritance. Never change insulin without your care team's instructions.

Your doctor is measuring your baby’s abdominal circumference (the measurement around their belly) because it helps the medical team estimate whether your baby inherited your GCK-MODY gene variant. This estimate is used to guide whether you might need insulin during your pregnancy [1]. In a GCK-MODY pregnancy, your slightly elevated blood sugar usually only affects the baby’s growth if they did not inherit the gene [2]. While a genetic test is the only way to know for sure, serial ultrasound measurements of the baby’s abdomen serve as a practical guide for your care [3][1].

Safety Warning: Never start, stop, or adjust insulin or other medications based on an ultrasound or this guide. Always follow the specific instructions of your maternal-fetal medicine and diabetes care teams.

The Fetal-Maternal Glucose Conflict

GCK-MODY acts like a raised thermostat for your blood sugar. Your body naturally and safely maintains a slightly higher baseline blood sugar level [1]. How this affects your pregnancy depends mainly on your baby’s genetics. Because you have a heterozygous GCK mutation, there is a 50% chance in each pregnancy of passing it to your baby.

  • If your baby inherited the GCK mutation: The baby’s blood sugar “thermostat” is raised just like yours [4]. They expect your slightly higher blood sugar levels and will generally grow normally [5]. If you take insulin to lower your blood sugar to a standard pregnancy target, it reduces the glucose available to the baby. This can deprive them of the energy they naturally expect, potentially causing them to be born too small (growth restriction) [5][4].
  • If your baby did NOT inherit the mutation: The baby has a typical blood sugar set point. Maternal glucose crosses the placenta, but maternal insulin does not. When the baby receives your slightly higher blood sugar, their pancreas produces more of its own insulin to handle it [1]. In a developing fetus, extra insulin acts as a powerful growth hormone. This can cause the baby to grow larger than normal (macrosomia), particularly around their abdomen [1][2].

Why the Abdominal Circumference Matters

When a baby produces extra insulin, the extra energy is stored as fat in their liver and abdomen [3]. This is why the abdominal circumference (AC)—measured during regular third-trimester ultrasounds—is closely tracked.

Doctors use this measurement as an indirect way to guide treatment:

  • Accelerated Growth: If the baby’s AC crosses a specific threshold used by your clinic’s protocol (often the 75th percentile) or grows rapidly, it suggests the baby may not have inherited the gene and is responding to the higher glucose [1][3]. Your team may prescribe insulin to lower your blood sugar, which reduces the risk of further excessive fetal growth [6].
  • Average Growth: If the AC remains stable and average, it suggests the baby may have inherited the gene. In this case, insulin is often unnecessary, and withholding it protects an affected baby from becoming too small [3].

It is completely normal to feel anxious when treatment decisions depend on estimating your unborn baby’s genetics. Keep in mind that an ultrasound is not a genetic test. A single large measurement does not prove the baby is unaffected—sometimes babies are just constitutionally large [7].

Genetic Testing Options

Because ultrasounds are an educated guess, you may want to discuss genetic testing with a genetic counselor or maternal-fetal medicine specialist:

  • Non-Invasive Prenatal Testing (NIPT/NIPD): In some regions, a specialized blood test can look at cell-free fetal DNA in your blood to determine if the baby inherited your specific GCK variant [8]. Availability and accuracy vary, and your specific familial mutation usually must be identified first [8].
  • Diagnostic Testing: Conventional tests like chorionic villus sampling (CVS) or amniocentesis can definitively confirm the baby’s genetics, though they carry a small risk of procedural complications that should be weighed against the benefits.

After Delivery

If you are prescribed insulin to manage fetal growth during pregnancy, your needs will change immediately after delivery. The baby’s and parent’s follow-up care, including blood sugar monitoring, should be discussed with your care team before you give birth.

Common questions in this guide

Why is my baby's abdominal circumference checked during a GCK-MODY pregnancy?
Serial measurements of the baby's abdominal circumference can show whether growth is accelerating or remaining average. In GCK-MODY, this pattern may provide an indirect clue about whether the baby inherited the GCK variant and help the care team decide whether insulin should be considered.
What does a high or rapidly increasing abdominal circumference mean?
A high or rapidly increasing abdominal circumference may suggest that the baby did not inherit the GCK variant and is responding to the mother's higher blood sugar with extra growth. It does not prove the baby's genetics, because some babies are naturally larger; your clinic will interpret the measurement using its own threshold and the full clinical picture.
Can an ultrasound confirm whether my baby inherited GCK-MODY?
No. Ultrasound can only provide an indirect estimate based on growth, while genetic testing is needed to confirm whether the baby inherited the familial GCK variant. A genetic counselor or maternal-fetal medicine specialist can discuss non-invasive fetal DNA testing, chorionic villus sampling, or amniocentesis.
Why might insulin be avoided if the baby inherited the GCK variant?
A baby who inherits the variant usually expects the mother's mildly higher blood sugar and may grow normally. Lowering maternal glucose to standard pregnancy targets with insulin can reduce the glucose available to that baby and may increase the risk of fetal growth restriction, so insulin decisions must be individualized.
When might insulin be recommended in a GCK-MODY pregnancy?
If serial ultrasounds show accelerated abdominal growth or the measurement crosses the threshold used by your clinic, the team may recommend insulin to reduce further excessive fetal growth. The measurement is not proof of inheritance, and you should not start or change insulin without your maternal-fetal medicine and diabetes teams.
What happens to my insulin plan after delivery?
Insulin needs can change immediately after delivery because the pregnancy-related reason for treatment may no longer be present. Ask your care team for a postpartum plan for your blood sugar and your baby's monitoring before birth, and do not adjust medication on your own.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you use ultrasound measurements, or do you offer specialized cell-free fetal DNA testing (NIPD) to determine if my baby inherited the GCK mutation?
  2. 2.At what specific percentile or growth rate for the baby's abdominal circumference would you recommend I start taking insulin?
  3. 3.If I do need to take insulin, how will we adjust my blood sugar targets to ensure the baby doesn't become too small, and what are the signs of low blood sugar I should watch for?
  4. 4.How often will my baby's growth be monitored with ultrasounds during the third trimester?
  5. 5.If I start insulin, how will my medication plan change immediately after delivery?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges.

    Timsit J, Ciangura C, Dubois-Laforgue D, et al.

    Frontiers in endocrinology 2021; (12()):802423 doi:10.3389/fendo.2021.802423.

    PMID: 35069449
  2. 2

    The Challenges of Treating Glucokinase MODY during Pregnancy: A Review of Maternal and Fetal Outcomes.

    Kirzhner A, Barak O, Vaisbuch E, et al.

    International journal of environmental research and public health 2022; (19(10)) doi:10.3390/ijerph19105980.

    PMID: 35627517
  3. 3

    Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives.

    Rudland VL

    Diabetes, metabolic syndrome and obesity : targets and therapy 2019; (12()):1081-1089 doi:10.2147/DMSO.S186610.

    PMID: 31372018
  4. 4

    Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.

    Chakera AJ, Steele AM, Gloyn AL, et al.

    Diabetes care 2015; (38(7)):1383-92 doi:10.2337/dc14-2769.

    PMID: 26106223
  5. 5

    Pregnancy outcome of Japanese patients with glucokinase-maturity-onset diabetes of the young.

    Hosokawa Y, Higuchi S, Kawakita R, et al.

    Journal of diabetes investigation 2019; (10(6)):1586-1589 doi:10.1111/jdi.13046.

    PMID: 30897270
  6. 6

    Pregnancy and neonatal outcomes in women with GCK-MODY: an observational study based on standardised insulin modalities.

    Ciangura C, Seco A, Saint-Martin C, et al.

    Diabetologia 2025; (68(5)):981-992 doi:10.1007/s00125-025-06363-0.

    PMID: 39971752
  7. 7

    Clinical and cost-effectiveness of non-invasive cell-free DNA testing to optimise foetal outcomes for women with monogenic diabetes due to inactivating glucokinase gene mutations: a case series.

    Jones AS, Kevat D, Lee IL, et al.

    Internal medicine journal 2025; (55(12)):2059-2064 doi:10.1111/imj.70262.

    PMID: 41263552
  8. 8

    Bringing precision medicine to the management of pregnancy in women with glucokinase-MODY: a study of diagnostic accuracy and feasibility of non-invasive prenatal testing.

    Hughes AE, Houghton JAL, Bunce B, et al.

    Diabetologia 2023; (66(11)):1997-2006 doi:10.1007/s00125-023-05982-9.

    PMID: 37653058

This page is for informational purposes only and does not constitute medical advice. Do not start, stop, or adjust insulin based on ultrasound findings; follow your maternal-fetal medicine and diabetes care teams for individualized guidance.

Get notified when new evidence is published on MODY.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.